Reporting Manager
Fairmount Funds Management LLC
Symbol
DNTH
Shares outstanding
40,929,818 shares
Disclosed Ownership
4,052,052 shares
Ownership
9.9%
Form type
SCHEDULE 13D/A
Filing time
15 Sep 2025, 16:15:29 UTC
Date of event
11 Sep 2025
Next filing
25 Nov 2025

Quoteable Key Fact

"Fairmount Funds Management LLC disclosed 9.9% ownership in Dianthus Therapeutics, Inc. /DE/ Common Stock, $0.001 par value (DNTH) on 11 Sep 2025."

Quick Takeaways

  • Fairmount Funds Management LLC filed SCHEDULE 13D/A for Dianthus Therapeutics, Inc. /DE/ Common Stock, $0.001 par value (DNTH).
  • Disclosed ownership: 9.9%.
  • Date of event: 11 Sep 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 15 Sep 2025, 16:15.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (5)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Fairmount Funds Management LLC 9.9% 4,052,052 0 4,052,052 /s/ Peter Harwin Peter Harwin, Managing Member 0001802528
Fairmount Healthcare Fund II L.P. 9.9% 4,052,052 0 4,052,052 /s/ Peter Harwin Peter Harwin, Managing Member 0001769651
Fairmount SPV III, LLC 0% 0 0 0 By: Fairmount Funds Management LLC, its Class A Member, /s/ Peter Harwin Peter Harwin, Managing Member
Peter Evan Harwin 9.9% 4,052,052 0 4,052,052 /s/ Peter Harwin Peter Harwin 0001663607
Tomas Kiselak 9.9% 4,052,052 0 4,052,052 /s/ Tomas Kiselak Tomas Kiselak 0001830177